Zacks Investment Research Lowers Alpine Immune Sciences (ALPN) to Sell

Zacks Investment Research cut shares of Alpine Immune Sciences (NASDAQ:ALPN) from a hold rating to a sell rating in a report published on Tuesday morning.

According to Zacks, “Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders and other diseases. Alpine Immune Sciences Inc., formerly known as Nivalis Therapeutics, is based in Seattle, Washington. “

Other equities analysts have also recently issued research reports about the stock. Raymond James started coverage on shares of Alpine Immune Sciences in a research report on Monday, August 13th. They set a buy rating and a $13.00 price target on the stock. Oppenheimer started coverage on shares of Alpine Immune Sciences in a research report on Friday, June 29th. They set an outperform rating and a $13.00 price target on the stock. Citigroup started coverage on shares of Alpine Immune Sciences in a research report on Thursday, June 28th. They set an outperform rating and a $13.00 price target on the stock. Piper Jaffray Companies started coverage on shares of Alpine Immune Sciences in a research report on Thursday, September 27th. They set an overweight rating and a $12.00 price target on the stock. Finally, ValuEngine raised shares of Alpine Immune Sciences from a strong sell rating to a sell rating in a research report on Thursday, August 2nd. Two equities research analysts have rated the stock with a sell rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of Hold and an average price target of $12.67.

Shares of ALPN stock traded up $0.09 during trading hours on Tuesday, hitting $5.29. The company has a debt-to-equity ratio of 0.05, a quick ratio of 20.99 and a current ratio of 20.99. Alpine Immune Sciences has a 52-week low of $4.89 and a 52-week high of $11.85. The company has a market capitalization of $72.69 million, a price-to-earnings ratio of -4.41 and a beta of 0.54.

Alpine Immune Sciences (NASDAQ:ALPN) last issued its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.13). Alpine Immune Sciences had a negative return on equity of 26.00% and a negative net margin of 1,602.19%. The company had revenue of $0.39 million for the quarter, compared to the consensus estimate of $0.30 million. As a group, research analysts forecast that Alpine Immune Sciences will post -2.12 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. DRW Securities LLC lifted its holdings in Alpine Immune Sciences by 138.7% in the second quarter. DRW Securities LLC now owns 24,343 shares of the biotechnology company’s stock worth $184,000 after acquiring an additional 14,143 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Alpine Immune Sciences by 20.9% in the second quarter. Renaissance Technologies LLC now owns 122,424 shares of the biotechnology company’s stock worth $927,000 after acquiring an additional 21,124 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in Alpine Immune Sciences by 122.2% in the second quarter. Dimensional Fund Advisors LP now owns 32,819 shares of the biotechnology company’s stock worth $248,000 after acquiring an additional 18,052 shares during the last quarter. 56.87% of the stock is currently owned by hedge funds and other institutional investors.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.

Read More: Stock Symbols and CUSIP Explained

Get a free copy of the Zacks research report on Alpine Immune Sciences (ALPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Alpine Immune Sciences (NASDAQ:ALPN)

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply